Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...
Zacks.com on MSN23h
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...
Innovaccer has raised a $275M Series F from investors including B Capital Group, Banner Health, Danaher Ventures, Generation ...
Professor Douglas Boateng, Board Chairman of the Minerals Income Investment Fund (MIIF), has underscored the potential of ...
We recently published a list of 10 Best Blue Chip Stocks to Buy for 2025. In this article, we are going to take a look at ...
Hosted on MSN12h
Lipozem: We Tested It (Update 2025)—Here’s Our Honest Lipozem Review After 113 Days!Maintaining a healthy body weight is essential for overall well-being, and many people are actively seeking natural solutions ...
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback